Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Companyâs research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Companyâs RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.

Employees

809

Sector

Biotechnology & Medical Research

Calendar

03-01 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
15/12/25	78.95 $	+0.04%	164,180
12/12/25	78.92 $	+0.52%	2,240,032
11/12/25	78.51 $	+0.81%	2,023,990
10/12/25	77.88 $	+0.09%	2,328,230
09/12/25	77.81 $	-2.81%	2,265,000

Delayed Quote Nasdaq, December 15, 2025 at 03:05 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

78.92USD

Average target price

82.65USD

Spread / Average Target

+4.73%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 15:20:14 15/12/2025 GMT			5-day change	1st Jan Change
79.18 ^USD	+0.32%		-1.57%	+80.16%

12-09	Akari Therapeutics, plc Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, Aktx-101, for Hard-To-Treat K-Ras Mutant Pancreatic Cancer	CI
11-24	Trading on Whispers Alone

Capitalization	15.26B 13B 12.14B 11.42B 21.03B 1,382B 22.98B 142B 54.97B 651B 57.25B 56.04B 2,377B	P/E ratio 2025 *	-14.1x	P/E ratio 2026 *	-12.6x
Enterprise value	14.99B 12.77B 11.92B 11.22B 20.66B 1,357B 22.57B 139B 53.99B 640B 56.23B 55.04B 2,334B	EV / Sales 2025 *	5,514x	EV / Sales 2026 *	559x
Free-Float	86.7%	Yield 2025 *	-	Yield 2026 *	-

12-09	Akari Therapeutics, plc Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, Aktx-101, for Hard-To-Treat K-Ras Mutant Pancreatic Cancer	CI
11-24	Trading on Whispers Alone
11-20	Revolution Medicines Insider Sold Shares Worth $939,008, According to a Recent SEC Filing	MT
11-20	Revolution Medicines Insider Sold Shares Worth $1,407,586, According to a Recent SEC Filing	MT
11-18	Revolution Medicines, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 09:30 AM
11-17	Revolution Medicines Insider Sold Shares Worth $1,301,410, According to a Recent SEC Filing	MT
11-13	Revolution Medicines Insider Sold Shares Worth $1,809,306, According to a Recent SEC Filing	MT
11-11	Revolution Medicines, Inc. Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference, Nov-11-2025 09:00 AM
11-06	Wedbush Lifts Price Target on Revolution Medicines to $80 From $77, Keeps Outperform Rating	MT
11-06	Revolution Medicines, Inc., Q3 2025 Earnings Call, Nov 05, 2025
11-05	Revolution Medicines Q3 Loss Widens	MT
11-05	Revolution Medicines Q3 net loss widens on higher clinical trial costs	RE
11-05	Revolution Medicines, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

11-06	Wedbush Lifts Price Target on Revolution Medicines to $80 From $77, Keeps Outperform Rating	MT
11-03	Revolution Medicines is Best-Positioned to Execute Targeting RAS-Mutated Cancers, RBC Says	MT
11-03	RBC Initiates Revolution Medicines at Outperform, Speculative Risk With $77 Price Target	MT
10-21	Mizuho Initiates Revolution Medicines at Outperform With $90 Price Target	MT
10-17	Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment	DJ

Revolution Medicines, Inc. Share Price

Equities

RVMD

US76155X1000

Biotechnology & Medical Research

Valuation: Revolution Medicines, Inc.

Chart: Revolution Medicines, Inc.

Latest news: Revolution Medicines, Inc.

Last Transcript: Revolution Medicines, Inc.

Analysts' recommendations: Revolution Medicines, Inc.

Press Releases: Revolution Medicines, Inc.

News in other languages: Revolution Medicines, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Revolution Medicines, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

11-05	Revolution Medicines : Corporate Presentation (5ec420)	PU
11-05	Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress	AQ
11-04	Revolution Medicines to Participate in November 2025 Investor Conferences	AQ
10-29	Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025	AQ
10-27	Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer	AQ

11-24	Wall Street : Investir au gré des rumeurs
10-24	BB Biotech redresse la barre au troisième partiel
10-24	BB Biotech profitiert von Erfolgen im Portfolio
10-10	Wall Street : Le Michigan à la rescousse
06-10	Wise: sluit recordjaar af en bereidt notering in New York voor

1 day	+0.06%
1 week	-1.57%
Current month	+1.34%
1 month	+13.97%
3 months	+70.56%
6 months	+98.14%
Current year	+80.16%

1 week	77.31	80.44
1 month	67.27	81.49
Current year	29.17	81.49
1 year	29.17	81.49
3 years	15.44	81.49
5 years	14.08	81.49
10 years	14.08	81.49

Manager	Title	Age	Since
Mark Goldsmith CEO	Chief Executive Officer	63	31/10/2014
Jack Anders DFI	Director of Finance/CFO	48	30/09/2018
Wei Lin CTO	Chief Tech/Sci/R&D Officer	63	31/03/2023

Director	Title	Age	Since
Mark Goldsmith CHM	Chairman	63	31/12/2019
Elizabeth Anderson BRD	Director/Board Member	67	28/02/2015
Alexis Borisy BRD	Director/Board Member	53	31/10/2014

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
REVOLUTION MEDICINES, INC.	+0.32%	-1.57%	+76.25%	+228.20%	15.26B
LONZA GROUP AG	+0.85%	-4.99%	-4.51%	+13.72%	45.43B
IQVIA HOLDINGS INC.	+0.04%	-0.55%	+12.81%	+6.68%	37.85B
BEONE MEDICINES AG	-5.27%	-5.90%	+74.23%	+47.76%	35.31B
CELLTRION, INC.	+0.54%	+2.45%	+6.04%	+17.19%	27.66B
MEDPACE HOLDINGS, INC.	+0.18%	+1.66%	+59.63%	+171.27%	15.72B
ICON PUBLIC LIMITED COMPANY	-1.29%	+1.97%	-9.05%	-2.70%	14.25B
ASCENDIS PHARMA A/S	-0.80%	+5.28%	+59.64%	+83.23%	13.47B
IONIS PHARMACEUTICALS, INC.	-0.77%	-1.45%	+110.84%	+110.29%	13.09B
TEMPUS AI, INC.	-2.14%	-10.57%	+72.77%	-	12.56B
Average	-0.91%	-0.81%	+45.86%	+75.07%	23.06B
Weighted average by Cap.	-0.88%	-1.42%	+35.59%	+53.83%

	2025 *	2026 *
Net sales	2.72M 2.32M 2.16M 2.03M 3.75M 246M 4.09M 25.24M 9.79M 116M 10.2M 9.98M 423M	27.27M 23.23M 21.7M 20.42M 37.59M 2.47B 41.07M 253M 98.26M 1.16B 102M 100M 4.25B
Net income	-1.06B -906M -846M -796M -1.47B -96.34B -1.6B -9.88B -3.83B -45.41B -3.99B -3.91B -166B	-1.23B -1.05B -980M -922M -1.7B -112B -1.85B -11.44B -4.44B -52.58B -4.62B -4.52B -192B
Net Debt	-272M -231M -216M -203M -374M -24.6B -409M -2.52B -979M -11.6B -1.02B -998M -42.31B	-